Abstract
Original article
Genovese MC et al. (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58: 2652–2661 PubMed